analiza aiqbench
This paper introduces AAbAAC, a specialized dataset designed to improve named entity recognition for autoimmune diseases using fine-tuned large language models. It highlights the necessity of domain-specific annotation efforts to bridge performance gaps that generalist AI models face in complex biomedical contexts like autoimmunity. The work contributes directly to advancing machine learning capabilities within niche scientific fields rather than addressing broader consumer or infrastructure issues.
AAbAAC: An Annotated Corpus for Autoimmunity Information Extraction
arXiv:2606.13051v1 Announce Type: new Abstract: Despite advances in information extraction driven by deep learning and large language models, performance gaps remain in highly specialized biomedical fields, where domainspecific complexity poses challenges for generalist models. In this work, we focus on the domain of autoimmunity, where the main entities of interest are autoimmune diseases, autoantibodies (i.e., molecules that may mark or cause these diseases), their molecular targets, their location in the body, and their associated clinical signs. Herein, we present AAbAAC (AutoAntibodies and Autoimmunity Annotated Corpus), a corpus of 115 abstracts selected from PubMed, where we manually annotated entities and their relationships. First, AAbAAC was used to evaluate several methods on the task of named entity recognition (NER), and secondly, to fine-tune NER models. Our study demonstrates the utility of AAbAAC for information extraction in the domain of autoimmunity, showing expected improvement in NER performance after finetuning. This illustrates the value of small-scale annotation efforts for specialized domains and contributes to the computational study of autoimmunity. The AAbAAC corpus is available at https://github.com/f-maury/AAbAAC.
Abstract:Despite advances in information extraction driven by deep learning and large language models, performance gaps remain in highly specialized biomedical fields, where domainspecific complexity poses challenges for generalist models. In this work, we focus on the domain of autoimmunity, where the main entities of interest are autoimmune diseases, autoantibodies (i.e., molecules that may mark or cause these diseases), their molecular targets, their location in the body, and their associated clinical signs. Herein, we present AAbAAC (AutoAntibodies and Autoimmunity Annotated Corpus), a corpus of 115 abstracts selected from PubMed, where we manually annotated entities and their relationships. First, AAbAAC was used to evaluate several methods on the task of named entity recognition (NER), and secondly, to fine-tune NER models. Our study demonstrates the utility of AAbAAC for information extraction in the domain of autoimmunity, showing expected improvement in NER performance after finetuning. This illustrates the value of small-scale annotation efforts for specialized domains and contributes to the computational study of autoimmunity. The AAbAAC corpus is available at this https URL.
Artificial Intelligence (cs.AI)
arXiv:2606.13051 [cs.AI]
(or arXiv:2606.13051v1 [cs.AI] for this version)
https://doi.org/10.48550/arXiv.2606.13051 Focus to learn more arXiv-issued DOI via DataCite (pending registration)
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.
Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.
Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Text integral sub licența deschisă a publicației · 263 cuvinte
Subiecte conexe

My experiences with the extremes of post-viral illness and brain retraining/mindbody work
LessWrong · 30 oct. 2026

Some different lenses of agency and their implications for alignment
LessWrong · 28 oct. 2026

Forbes Asia 100 To Watch 2026
forbes.com · 24 aug. 2026

AI is giving cybercrime a makeover, and this startup just raised $15 million to fight back
Fortune · 26 oct. 2026